Respiratory Conditions

Researchers find that inpatient utilization was 53% higher among patients with exacerbations.

A generic fluticasone from Glenmark Specialty will be available this month, but there is no information yet on pricing.

The researchers caution, though, that causality cannot be inferred from the association found in an observational study.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

A team of Researchers developed a "recovery index" that integrates three factors related to the six-minute walk test.

Stereotactic ablative radiotherapy, also referred to as stereotactic body radiation therapy, has emerged as a standard noninvasive treatment alternative, offering high local control rates with relatively limited toxicity in carefully selected patients.

Because familial idiopathic pulmonary fibrosis is associated with earlier onset and worse outcomes, there are questions about the effectiveness of the antifibrotics as a treatment.

Several lines of evidence suggest that testing the traditional drug for diabetes might benefit people with idiopathic pulmonary fibrosis.

The approval comes two months after Jascayd (nerandomilast) was approved for idiopathic pulmonary fibrosis.

The new radiotracer takes advantage of two biological targets linked to fibrotic and inflammatory processes in the lung: fibroblast activation protein and integrin receptors.

Given the long latency and broad spectrum of respiratory conditions associated with military deployment, the findings underscore the need for long-term medical surveillance and specialized respiratory care for veterans.

The AI-powered imaging technology quantifies the extent of fibrosis on CT scans and also measures other features, such as ground-glass opacification.

Researchers used a data textural analysis to quantify changes seen on high-resolution CT scans.

An off-target interaction with nuclear receptor PPARγ may trigger a sequence of events that results in lung injury.

The results of the FIBRONEER trial were the basis for the FDA approval of nerandomilast in October 2025.

Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both fibrosis and the immune system. It will be available in the next few weeks.

The differing regulation of key fibrotic pathways suggest that idiopathic pulmonary fibrosis involves dysregulation rather than just a speeded-up aging process.

The deuterated form of deupirfenidone produced favorable results in an open-label extension study.

Therapies targeting extracellular matrix remodeling might hold the most promise.